Competitor Analysis: Targeted Therapy of Hepatitis C - Market Research Reports

Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1071076

Competitor Analysis: Targeted Therapy of Hepatitis C

Description:

The present Competitive Intelligence Report about Targeted Therapy of Hepatitis C provides a competitor evaluation in the field of specifically targeted antiviral therapeutics for hepatitis C (STAT-C) as of August 2009. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Most hepatitis C virus (HCV) infected individuals seeking treatment are chronically infected. Treatment goal is to achieve a sustained virological response (SVR), which is the absence of serum HCV RNA up to 6 months after therapy is concluded. To increase efficiency of interferon treatment, pegylated interferon alpha (peg-IFN-alpha) therapy has been supplemented with ribavirin. Combination therapy with peg-IFN-alpha and ribavirin has resulted in a further increase in treatment efficiency with 54% of HCV infected patients achieving SVR. The response and rate of SVR is dependent on the genotype of HCV with only 30% of genotype 1 infected individuals achieving SVR, whereas greater than 80% of genotype 2 or 3 achieve SVR with combination therapy. Combination therapy treatment regiments are genotype dependent and the amount of peg-IFN-a administered is dependent on the type used.

The suboptimal response has led to a shift in the investigational focus for treatment of HCV toward specifically targeted antiviral therapy for HCV agents. Moreover, pegylated IFN alpha and/or ribavirin are associated with frequent side effects and have a negative impact on the patient's quality of life. Among the first wave of targeted HCV therapeutics are the NS3a protease and NS5B RNA polymerase inhibitors with 25 different compounds in clinical development and further 8 in the IND enabling study phase. Development of HCV protease inhibitors is slightly ahead of polymerase inhibitors. The first study combining HCV protease and polymerase inhibitors was successfully completed.

At least 17 further distinct molecules are in early clinical development and another five close to enter clinical investigation which have novel mechanisms of action. Among the targets are cyclophilin inhibitors, NS5A protein inhibitors, NS4B-RNA binding inhibitors, viral entry and replication inhibitors. Specific therapeutic vaccines and antibodies are included in those novel targeted HCV treatment modalities. Other novel mechanism of action agents are directed against host cell or viral structures.

The report includes a compilation of current active projects in research and development of molecules specifically directed against novel targets in hepatitis C. In addition, the report lists company-specific R&D pipelines of targeted therapeutics in hepatitis C. Competitor projects are listed in a tabular format providing information on:

- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.

Contents:

Index:

- HCV Protease Inhibitors

- HCV RNA Polymerase Inhibitors

- Cyclophilin Inhibitors

- HCV NS5A Protein Inhibitors

- HCV NS4B-RNA Binding Inhibitors

- Therapeutic HCV Vaccines

- Therapeutic HCV Antibodies

- HCV Viral Entry Inhibitors

- HCV Replication Inhibitors

- Novel Mechanism of Action HCV Virus Targets

- Novel Mechanism of Action HCV Host Cell Targets

- Corporate Targeted Hepatitis C Therapeutic R&D Pipelines

- About La Merie

Ordering:

Order Online - visit http://www.researchandmarkets.com/reports/1071076

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Page 1 of 2
Printed 27/11/2009 18:36:45

Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.


Product Name:
Competitor Analysis: Targeted Therapy of Hepatitis C
Web Address:
http://www.researchandmarkets.com/reports/1071076
Office Code:
OC8HJNPOUMUXU

Report formats
Please enter the quantity of the report format you require.

Format	Quantity	Price
Electronic (PDF) - Single User		€500.00
Electronic (PDF) - Site License		€1,000.00
Electronic (PDF) - Enterprisewide		€1,500.00

Contact information
Please enter all the information below in BLOCK CAPITALS.


	First Name:	Last Name:
	Email Address:
	Job Title:
	Organisation:
	Address:
	City:
	Postal/Zip Code:
	Country:
	Phone Number:
	Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed 27/11/2009 18:36:45

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

	American Express
	Diners Club
	Master Card
	Visa


Cardholder's Name:

Cardholder's Signature:

Expiry Date:	/

Card Number:

CVV Security Code:

Issue Date:	/ (Diners Club only)

Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Pay by Wire Transfer:

Please transfer funds to:


Account number:	83313083
Sort code:	98-53-30
Swift code:	ULSBIE2D
IBAN number:	IE78ULSB98533083313083
Bank Address:	Ulster Bank, 27-35 Main St, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:
	Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)